Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $255,844.68 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 23,429 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $10.92, for a total value of $255,844.68. Following the completion of the sale, the chief executive officer directly owned 1,449,765 shares in the company, valued at approximately $15,831,433.80. This trade represents a 1.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV opened at $10.22 on Friday. The firm has a market capitalization of $499.66 million, a P/E ratio of -3.10 and a beta of 2.18. The business has a 50 day simple moving average of $10.67 and a 200 day simple moving average of $8.97. Artiva Biotherapeutics, Inc. has a 12-month low of $2.22 and a 12-month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.63). Research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several large investors have recently bought and sold shares of the stock. 5AM Venture Management LLC bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth about $22,827,049. Blue Owl Capital Holdings LP bought a new position in shares of Artiva Biotherapeutics in the second quarter valued at approximately $8,483,000. Citadel Advisors LLC boosted its holdings in shares of Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after acquiring an additional 644,658 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $6,739,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $2,910,000.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Needham & Company LLC restated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wall Street Zen upgraded Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.